Group 1: Company Insights - Longsheng Fund recently conducted research on two listed companies: iFlytek and Prolo Pharmaceutical [1][2] - iFlytek has accumulated over 50TB of industry corpus and over 1 billion user interactions daily, enhancing its data quality and multi-modal capabilities with the upgrade of its "Xunfei Spark Model" to version 4.0, which benchmarks against GPT-4 Turbo [1] - Prolo Pharmaceutical has established long-term partnerships with leading global pet medicine companies and has products targeting aging populations, such as sustained-release metoprolol and indapamide for hypertension [2] Group 2: Financial Performance - Longsheng Fund, established in 1999, has an asset management scale of 96.309 billion yuan, ranking 64th out of 210 in total public funds [2] - The fund's non-monetary public fund management scale is 65.487 billion yuan, ranking 63rd out of 210 [2] - The best-performing public fund in the past year is the Longsheng Urbanization Theme Mixed C, with a latest net value of 2.67 and a growth of 84.29% over the past year [2]